When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
RLAY - Dosing underway in Relay Therapeutics' first-in-human RLY-4008 trial
Relay Therapeutics Inc.
Relay Therapeutics (NASDAQ:RLAY) has dosed the first patient in a first-in-human clinical trial of RLY-4008 enriched for patients with intrahepatic cholangiocarcinoma (ICC) and other advanced solid tumors harboring a fibroblast growth factor receptor 2 (FGFR2) alteration.
More news on: Relay Therapeutics, Inc., Healthcare stocks news,